Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Standard treatment for lung cancer should be changed, say scientists

24.09.2003


Patients with non-small cell lung cancer (NSCLC) are more likely to survive if they have chemotherapy after surgery than if they have surgery alone, said a scientist at ECCO 12 The European Cancer Conference in Copenhagen today (Tuesday 23 September). Dr. Bengt Bergman, of the Sahlgrenska University Hospital. Göteborg, Sweden, said that results from the International Adjuvant Lung Cancer Trial (IALT), which involved 1,867 patients in 33 countries, were sufficiently strong to recommend changing the standard treatment.



The randomised controlled trial showed an absolute 4.1% increase in survival after five years among those who had had adjuvant therapy with cisplatin, in combination with one of several other commonly-used cancer drugs. A 1995 meta-analysis of other trials showed a similar advantage for this therapy, but with only a borderline statistical significance since fewer patients with cisplatin treatment were included, said Dr. Bergman.

Recurrence of lung cancer was also reduced in the cisplatin arm of the trial. After 5 years 24% of those taking cisplatin had a local recurrence, whereas this occurred in 29% of the control arm. The study found no interaction between dose or treatment combination and survival benefit.


The trial was the first with sufficient numbers of patients to show a statistically significant survival benefit from adjuvant chemotherapy in NSCLC, said Dr. Bergman. "Although a 4.1% improvement may not seem very much on which to base recommending a change in treatment, it is in line with results from other common malignancies such as breast, ovarian, and colon cancer, where the survival gain from adjuvant chemotherapy lies in the range of 3.5 – 8%. In all these cases adjuvant treatment is now part of the routine treatment."

However, toxicity remains a problem, he said. "There are potentially serious side effects to this treatment, and we need better tools to identify the patients who are most likely to benefit from adjuvant chemotherapy. The IALT project includes an extended research programme which aims to identify predictive tumour markers. And a planned joint analysis of the largest recent trials of adjuvant cisplatin-based therapy including more than 4,000 patients will better enable us to detect factors allowing us to predict treatment effects."


###

Emma Mason | EurekAlert!
Further information:
http://www.fecs.be/

More articles from Health and Medicine:

nachricht Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Tracking movement of immune cells identifies key first steps in inflammatory arthritis

23.01.2017 | Health and Medicine

Electrocatalysis can advance green transition

23.01.2017 | Physics and Astronomy

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>